A solid science and the right patent, keys to raise private funding

by GENESIS Biomed

6 years ago
solid science, patent, funding, health, ITEMAS, CORIFY CARE, GLYCARDIAL, APTATARGETS

Having a solid scientific project and the right patent to protect it are key to raise funding in health innovation projects, according to the three entrepreneurs that participated in the 3rd webinar o...

The keys to raise private funding: evaluation of an innovation project

by GENESIS Biomed

6 years ago
investor, Ysios Capital, private funding, innovation, ITEMAS, competition, Arvor Global Management

Raising private funding is essential for an innovation project to progress and reach market. ITEMAS 2nd webinar of the series about Investment in Covid-19 times tackled the key steps for entrepreneurs...

A key tool for the future of Alzheimer’s disease research

by GENESIS Biomed

6 years ago
Alzheimer, neurogenerative, artificial intelligence, Pasqual Maragall Foundation

Doctor Juan Domingo Gispert and his team, from Barcelona Beta Brain Research Center, work in a tool to improve the selection of patients for Alzheimer’s prevention studies

ITEMAS is in favour of the creation of a fund or investment instrument for early stage projects

by GENESIS Biomed

6 years ago
industrial property, fund, early stage, ITEMAS, medical centres, investment

Which are the needs of innovation projects born in medical centres? Which are the limitations to bring them to market? Innovation experts gave their views at the 1st ITEMAS webinar about “Investm...

We could hit a new milestone in the treatment of infertility

by GENESIS Biomed

6 years ago
Oxolife, assisted reproduction, women, infertility, treatment

Agnès Arbat and Ignasi Canals lead Oxolife, a startup that is developing OXO-001, a drug with the potential to treat female infertility as it increases the chances of embryo implantation a 65%. Arba...

EVERAI will save lives with data

by GENESIS Biomed

6 years ago
ambulance, EVERAI, software

Since May 28th EVERAI Medical Technologies is a new legally constituted start-up. For the last months its team has been working in the development of a software that will facilitate exchanging live-sa...

Droplite opens seed round of 600.000€ to accelerate the manufacturing development of its smart medical diagnostics device

by GENESIS Biomed

6 years ago
Droplite, platform, medical diagnostics device

Droplite,a spinoff of the Institute of Photonics Ciences (ICFO), located in the vibrant Parc Cientific de Barcelona (PCB), has recently started the industrial design and manufacturing development o...

Dejar de fumar con un chatbot: el reto de Déjalo Bot

by GENESIS Biomed

6 years ago
Déjalo Bot, fumar, SALUD, tabaquísmo, fármaco

Dejar de fumar continua siendo un reto muy difícil de superar. Los estudios poblacionales muestran que a la mayoría de fumadores les gustaría abandonar el tabaco y que un elevado porcentaje lo ...

Estamos ante lo que puede ser un nuevo hito en el tratamiento de la infertilidad

by GENESIS Biomed

6 years ago
Kern Pharma, Bayer, Oxolife, infertilidad

Agnès Arbat y Ignasi Canals lideran Oxolife, una startup que desarrolla OXO-001, un fármaco con el potencial de tratar la infertilidad femenina al incrementar en un 65% la implantación embrionar...

ADmit Therapeutics, backed by Ship2B, GENESIS Biomed and BStartup, obtains the support of the Alzheimer’s Drug Discovery Foundation

by GENESIS Biomed

6 years ago
ADmit Therapeutics, Ship2B, Startup, Alzheimer

ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnost...

Genesis Ventures participa en la ronda de €600.000 abierta por Droplite para acelerar la fabricación de su dispositivo de diagnóstico en tiempo real

by GENESIS Biomed

6 years ago
Droplite, Genesis Biomed, Genesis Ventures

El dispositivo de diagnóstico desarrollado por Droplite se basa en el concepto lab-on-a-chip y es capaz de realizar pruebas rápidas de tipo inmunoensayo con la fiabilidad de un laboratorio central. ...